Lemtrada (alemtuzumab)

However, in the past few years, few cases have come forward in which after treatment with a monoclonal antibody, Alemtuzumab, patients developed sarcoidosis. This antibody targets the pan-lymphocyte CD52 antigen found on both human lymphoid and myeloid cells and is used in the treatment of Relapsing Remitting Multiple Sclerosis, leukemia, etc. Patients, in these cases, after a few years of treatment developed sarcoidosis but fortunately responded well to the treatment, if needed.

P=N/A, N=4000, Completed, University of British Columbia

P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial primary completion date: Apr 2030 --> Jul 2027

P4, N=800, Active, not recruiting, The Cleveland Clinic | Recruiting --> Active, not recruiting

P=N/A, N=15, Active, not recruiting, Queen Mary University of London

P=N/A, N=1178, Recruiting, Biogen | N=825 --> 1178

Our case describes a severe autoantibody-induced encephalitis in a young patient with MS, with alemtuzumab as a potential trigger for anti-GABA-A receptor encephalitis.

All national publicly-available aggregated ADR reports recorded from 2002 to 2020 into the Reports of Adverse Reactions of Medicines (RAM) system and all complete Sicilian data reported into the Italian spontaneous reporting system (SRS) database having as suspected drugs interferon β-1a (IFN β-1a), interferon β-1b (IFN β-1b), peginterferon β-1a (PEG-IFN β-1a), glatiramer acetate (GA), natalizumab (NTZ), fingolimod (FNG), teriflunomide (TRF), dimethyl fumarate (DMF), alemtuzumab (Alem), ocrelizumab (OCZ), or cladribine (Cladr), were collected...The reporting of drugs-related ADRs in MS were mostly reported in the literature, but some unknown ADRs were also found. However, further studies are necessary to increase the awareness about the safety profiles of new drugs on the market.

There are several reports of GBS after alemtuzumab treatment in patients with leukemia.However,in MS patients,there is only one published case of acute motor axonal neuropathy that occurred after the alemtuzumab treatment.GBS should also be considered in patients with subacute neurological worsening after the alemtuzumab treatment.

Context: T-cell prolymphocytic leukemia (T-PLL) is an extremely rare mature T-cell neoplasm associated with an aggressive clinical course, poor response to conventional chemotherapy, and a dismal prognosis. The patient presented in this case study was treated with conventional chemotherapy alone and achieved CR of T-PLL, maintaining the treatment response to date (3 months after completion of the therapy). Despite this, alemtuzumab remains a crucial element in the arsenal of treatment for T-PLL, and its lack of availability poses a serious challenge for clinicians.

All consecutive reports of DMTs prescribed to pwMS (alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon-β, natalizumab, ocrelizumab, and teriflunomide), and their serious adverse event cases were eligible, excluding those reporting immunosuppressant DMTs used as anticancer therapies...A close and regular cancer screening in pwMS treated with natalizumab, interferon-β, dimethyl fumarate, and fingolimod may be warranted, even for persons at a younger age. Trial Registration NCT04237337.